Volume 3, Issue 1, March 2019, Page: 1-6
The Diagnostic Role of p53 and Ki 67 Immunohistochemistry in Evaluation of Urinary Bladder Carcinomas in Egyptian Patients
Sahar Ali Mohamed, Department of Pathology, General Organization of Teaching Hospitals and Institutes (GOTHI), Cairo, Egypt
Received: Apr. 23, 2019;       Accepted: May 30, 2019;       Published: Jun. 10, 2019
DOI: 10.11648/j.ijcm.20190301.11      View  22      Downloads  7
Abstract
Background: Urothelial carcinomas (UC) are the most common cancers of urinary bladder responsible for a significant proportion of cancer morbidity and mortality. In Egypt, bladder cancer is the second most common malignancy. We did the present investigation to exhibit the clinicohistopathological highlights and to associate the p53 and Ki 67 immunoexpression with grade and stage of bladder carcinomas. Materials and Methods: sixty-two cases of bladder neoplasm were investigated. Grading and staging was done. An immunohistochemical assay for p53 and Ki 67 was performed in altogether cases, with relation to clinicopathological parameter. Results: There was a significant association of p53 and Ki 67 overexpression in high grade with the epithelial type (P=0.0001) & (P=.0.01) respectively. While there was a statistically significant association of high expression of P53 in PT1 compared to PTa and PT2 (p=0.000001). There was a significant correlation between Ki 67 in staging pT1 (pTa + pT1/pT2, P = 0.000001; pTa/ pT1, P = 0.000001; pT1/pT2, P = 0.000002). Conclusion: The role of p53 and Ki 67 immunohistochemical relativities in the differential diagnosis and prognosis of urinary bladder carcinomas in step with the pathological stage and histologic grade of the neoplasm, will be understood due to unique biology and pathogenic features of these tumors. Thus, this study supports the opinion that combined use of p53 and Ki 67 immunostaining markers may help as further prognostic clue alongside with histologic grading and staging in bladder carcinomas.
Keywords
Urinary Carcinomas, p53, Ki 67, Urothelial, Prognosis, Stage, Grade
To cite this article
Sahar Ali Mohamed, The Diagnostic Role of p53 and Ki 67 Immunohistochemistry in Evaluation of Urinary Bladder Carcinomas in Egyptian Patients, International Journal of Chinese Medicine. Vol. 3, No. 1, 2019, pp. 1-6. doi: 10.11648/j.ijcm.20190301.11
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Mingshan Li, 1 YixiangWang, 1 Yili Liu, 1 Xiling Zhang, 1 Jie Liu, 2 and Ping Wang. Low Expression of hsa_circ_0018069 in Human Bladder Cancer and Its Clinical Significance. Hindawi BioMed Research International, 2019; Article ID 9681863, 9 pages https://doi.org/10.1155/2019/9681863
[2]
da Silva, J. N. L., Ranzi, A. D., Carvalho, C. T. et al. Pathol. Oncol. Res. (2018). https://doi.org/10.+1007/s12253-018-0389-5
[3]
Siegel RL, Miller KD, and Jemal A. (2017) Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7-30es.
[4]
Compérat E et al, Comparaison des classifications TNM des 8 éditions de l’UICC et de JCCenuropathologie Comparison of UICC and AJCC 8th edition TNM classifications in uropathology. Annales de Pathologie. 2019; 39 (2): 158-166.
[5]
Kandori S, Kojima T, Nishiyama H. The updated points of TNM classification of urological cancers in the 8th edition of AJCC and UICC, Japanese Journal of Clinical Oncology. 2019; 49 (5): 421-425 https://doi.org/10.1093/jjco/hyz017.
[6]
Xylinas E, Kluth LA, Lotan Y, Daneshmand S, Rieken M, Karakiewicz PI et al Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. Urol Oncol. 2014 32: 230–242.
[7]
ElkadyN, Sultan M, Elkhouly E. Evaluation of topoisomerase II, ki-67, and P53 expression in non-muscle-invasive urothelial carcinoma and their clinical significanc. 2018; 61 (4): 526-531.
[8]
Wu P et al. Low-level Ki-67 expression as an independent predictor of bladder tumour recurrence in patients with primary upper tract urothelial carcinoma after radical nephroureterectomy. Japanese Journal of Clinical Oncology, 2015, 45 (12) 1175–1181 doi: 10.1093/jjco/hyv139.
[9]
Qamar S, Inam QA, Ashraf S, Khan MS, Khokhar MA, Awan N. Prognostic Value of p53 Expression Intensity in Urothelial Cancers. J Coll Physicians Surg Pak. 2017 Apr; 27 (4): 232-236. doi: 2596.
[10]
Kyritsi F, Christopher A. Loffredo, Yun-Ling Zheng, George Philips, and Sania Amr, “Urinary Bladder Cancer in Egypt: Are There Gender Differences in Its Histopathological Presentation?,” Advances in Urology, vol. 2018, Article ID 3453808, 7 pages, 2018. https://doi.org/10.1155/2018/3453808
[11]
Shebl AM, Zalata KR, Amin MM, El-Hawary AK (2011). An inexpensive method of small paraffin tissue microarrays using mechanical pencil tips. Diagn Pathol, 2011; 6, 117.
[12]
Soliman NA and Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biology & Medicine. 2016; 13 (4), 496-504.
[13]
Thakur B., Kishore S, Dutta K., Kaushik S. and Bhardwaj A. Role of p53 and Ki-67 immunomarkers in carcinoma of urinary bladder. Indian J Pathol M. 2017; 60: (4); 505-509.
[14]
Poyet C, Jentsch B, Hermanns T, Schweckendiek D, Seifert H-H, Schmidt peter M, Sulser T Et al. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin Pathol 2014; 14: 10.
[15]
Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MBUpdates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol. 2018; 73 (4): 560-569. doi: 10.1016/j.eururo.
[16]
Gupta P, Jain M, Kapoor R, Muruganandham K, Srivastava A, Mandhani A. Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J Urol 2009; 25: 207-10.
[17]
Sathya M, Chinnaswamy P. Urinary bladder cancer: A clinicopathological and histological study J Med Sci 2014; 14: 206-9.
[18]
Koyuncuer A. Immunohistochemical expression of p63, p53 in urinary bladder carcinoma Indian J Pathol Microbiol. 2013; 56: (1); 10-15.
[19]
Geelvink M et al. Diagnostic and Prognostic Implications of FGFR3high/Ki67high Papillary Bladder Cancers. Int. J. Mol. Sci. 2018, 19, 2548; doi: 10.3390/ijms19092548.
[20]
Pudasaini S, Subedi N, Prasad KB, Rauniyar SK, Joshi BR, Bhomi KK. Cystoscopic bladder biopsies: A histopathological study. Nepal Med Coll J 2014; 16: 9-12.
[21]
Beltran H, Robinson BD, Tagawa ST. Primary squamous cell carcinoma of the urinary bladder presenting as peritoneal carcinomatosis. Adv Urol 2010; Vol. 2010 Article ID 179250.
[22]
Matsushita K, Cha EK, Matsumoto K, Baba S, Chromecki TF, Fajkovic Hetal. Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol 2011; 18: 616–629.
[23]
Luo Y, Zhang X, Mo M, Tan Z, Huang L, Zhou H, et al. High Ki-67 immunohistochemical reactivity correlates with poor prognosis in bladder carcinoma: A comprehensive meta-analysis with 13,053 patients involved. Medicine (Baltimore) 2016; 95: e3337.
[24]
Turk NS, Aybek Z, Duzcan E. Ki-67, p53, Bcl-2 and bax expression in urothelial carcinomas of urinary bladder. Turk J Pathol 2010; 26: 25-30.
Browse journals by subject